Analysts expect Flex Pharma Inc (NASDAQ:FLKS) to report $370,000.00 in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Flex Pharma’s earnings, with the highest sales estimate coming in at $400,000.00 and the lowest estimate coming in at $320,000.00. Flex Pharma posted sales of $300,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 23.3%. The company is expected to report its next quarterly earnings results on Wednesday, March 14th.
On average, analysts expect that Flex Pharma will report full year sales of $370,000.00 for the current year, with estimates ranging from $1.32 million to $1.40 million. For the next financial year, analysts anticipate that the company will report sales of $3.75 million per share, with estimates ranging from $1.41 million to $5.43 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Flex Pharma.
Flex Pharma (NASDAQ:FLKS) last issued its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.06. Flex Pharma had a negative return on equity of 71.39% and a negative net margin of 2,655.19%. The firm had revenue of $0.41 million during the quarter, compared to the consensus estimate of $0.47 million.
A hedge fund recently bought a new stake in Flex Pharma stock. Sphera Funds Management LTD. acquired a new position in Flex Pharma Inc (NASDAQ:FLKS) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 141,300 shares of the biotechnology company’s stock, valued at approximately $2,341,000. Sphera Funds Management LTD. owned approximately 0.79% of Flex Pharma as of its most recent filing with the Securities and Exchange Commission. 27.31% of the stock is owned by institutional investors and hedge funds.
Flex Pharma (NASDAQ FLKS) opened at $3.85 on Friday. Flex Pharma has a twelve month low of $2.68 and a twelve month high of $5.93. The firm has a market capitalization of $70.99 and a price-to-earnings ratio of -1.91.
TRADEMARK VIOLATION NOTICE: “Zacks: Brokerages Anticipate Flex Pharma Inc (FLKS) Will Announce Quarterly Sales of $370,000.00” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2018/01/20/zacks-brokerages-anticipate-flex-pharma-inc-flks-will-announce-quarterly-sales-of-370000-00.html.
About Flex Pharma
Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Flex Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma and related companies with MarketBeat.com's FREE daily email newsletter.